<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9282">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05701384</url>
  </required_header>
  <id_info>
    <org_study_id>SMC 2023-01-17</org_study_id>
    <nct_id>NCT05701384</nct_id>
  </id_info>
  <brief_title>Lazertinib 160mg in EGFR T790M NSCLC</brief_title>
  <official_title>A Phase II Study for the Evaluation of the Feasibility of Lazertinib 160mg Per Day in Patients With EGFR T790M Mutant Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The lazertinib is currently approved as 2nd line T790M mutation-positive NSCLC that failed&#xD;
      from either 1st or 2nd generation EGFR TKI. The current recommended dosage is 240mg. Based on&#xD;
      the promising clinical efficacy of the dose escalation study, this study is designed to&#xD;
      evaluatee the clinical efficacy and safety of 160mg lazertinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2023</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The dose reduction or treatment discontinuation rate</measure>
    <time_frame>Total 24 months of study period</time_frame>
    <description>Dose who received dosage below 160mg or discontinued due to the adverse event</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Lung Cancer Stage IV</condition>
  <condition>EGFR T790M</condition>
  <arm_group>
    <arm_group_label>Lazertinib 160mg arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lazertinib</intervention_name>
    <description>160mg po qd</description>
    <arm_group_label>Lazertinib 160mg arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed non-small cell lung cancer&#xD;
&#xD;
          -  Patients in a palliative setting who is not applicable for the curative treatment&#xD;
&#xD;
          -  EGFR mutation positive patients who received previous 1st or 2nd generation EGFR TKI&#xD;
&#xD;
          -  Confirmed EGFR T790M mutation after the previous EGFR TKI&#xD;
&#xD;
          -  Available to receive lazertinib either as po or vis levine tube&#xD;
&#xD;
          -  Willing to participate clinical trial&#xD;
&#xD;
          -  Age over or equal to 19&#xD;
&#xD;
          -  ECOG PS 0 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously received 3rd generation EGFR TKI&#xD;
&#xD;
          -  No clinical benefit is expected based on the investigator's decision&#xD;
&#xD;
          -  Uncontrolled symptomatic CNS metastases&#xD;
&#xD;
          -  Uncontrolled systemic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>MA</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 17, 2023</study_first_submitted>
  <study_first_submitted_qc>January 26, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>January 26, 2023</last_update_submitted>
  <last_update_submitted_qc>January 26, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jong-Mu Sun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lazertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The only clinical outcome data will be published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

